You are viewing the site in preview mode

Skip to main content

Advertisement

Table 4 Generalized Estimated Equation saturated model: Associations between virologic and immunologic failure with baseline and clinical characteristics

From: Virologic and immunologic failure, drug resistance and mortality during the first 24 months postpartum among HIV-infected women initiated on antiretroviral therapy for life in the Mitra plus Study, Dar es Salaam, Tanzania

Variable Virologic failure Odds ratio* (OR) 95% CI p-value Immunologic failure Odds ratio* (OR) 95% CI p-value
Month 6 1.54 0.65-3.67 0.329 3.49 0.48-25.66 0.219
Month 12 9.64 2.92-31.86 0.000 6.57 1.17-36.90 0.032
Month 24 45.88 10.07-208.96 0.000 9.78 1.16-81.30 0.035
Age 0.91 0.78-1.05 0.197 0.78 0.47-1.29 0.333
Education 0.92 0.82-1.04 0.191 0.89 0.65-1.00 0.053
Not married 2.88 0.46-17.96 0.257 0.02 0.00-18.35 0.271
Gravidity 1.49 0.68-3.25 0.317 0.86 0.42-1.87 0.746
Parity 0.74 0.30-1.80 0.506 1.08 0.34-3.43 0.898
Disclosed HIV status 0.84 0.17-4.18 0.829 4.94 0.58-42.19 0.144
Partner HIV unknown 0.75 0.19-2.95 0.675 3.63 0.07-181.81 0.519
Partner HIV positive 4.21 0.60-29.38 0.147 1.94 0.03-139.79 0.761
Hemoglobin 0.75 0.54-1.03 0.071 0.32 0.07-1.47 0.143
Not adherent month 6 2.15 0.57-8.09 0.256 2.85 0.20-41.10 0.442
Not adherent month 24 10.01 2.29-43.66 0.002 30.98 1.31-733.91 0.033
  1. *Odds Ratio adjusted for all variables in the table.